Signalling pathways in endometrial cancer

Wspolczesna Onkologia

Volumn 18, Issue 3, 2014, Pages 143-148

  Markowska, Anna ^a   Pawałowska, Monika ^a   Lubin, Jolanta ^a   Markowska, Janina ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Akt PI3k pathway; Endometrial cancer; P16; P53; Signalling pathways; Wnt catenin

Indexed keywords

APC; AXIN; BETA CATENIN; CYCLIN D; CYCLIN DEPENDENT KINASE; DNA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; WNT PROTEIN;

AKT GENE; APC GENE; APOPTOSIS; AXIN GENE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; CTNBB1 GENE; DNA REPAIR; ENDOMETRIUM CANCER; ENZYME INACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE P16; GENE P53; HUMAN; NONHUMAN; ONCOGENE; PIK3CA GENE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

EID: 84905484008     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.43154     Document Type: Review

References (49)

1. Gallorini M, Cataldi A, di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs 2012; 26: 377-91.
2. Błasiak J, Majsterek J, Pytel D. Kinazy tyrozynowe. Nowy cel terapii przeciwnowotworowej. Postȩpy Biochemii 2005; 51: 251-60.
3. Yeramian A, Moreno-Bueno G, Dolcet X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 2013; 32: 403-13.
4. Coombs GS, Covey TM, Virshup DM. Wnt signaling in development, disease and translational medicine. Curr Drug Targets 2008; 9: 513-31.
5. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387-98. (Pubitemid 351589714)
6. Terasaki H, Saitoh T, Shiokawa K, Katoh M. Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway. Int J Mol Med 2002; 9: 107-12.
7. Katoh Y, Katoh M. Identification and characterization of rat Wnt6 and Wnt10a genes in silico. Int J Mol Med 2005; 15: 527-31.
8. Janssens N, Janicot M, Perera T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs 2006; 24: 263-80.
9. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51. (Pubitemid 46109296)
10. Peters JM, McKay RM, McKay JP, Graff JM. Casein kinase I transduces Wnt signals. Nature 1999; 401: 345-50. (Pubitemid 29454951)
11. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. The soluble Wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 2007; 67: 5371-9. (Pubitemid 46997277)
12. Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A 2012; 109: 11717-22.
13. Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget 2012; 3: 1546-56.
14. van der Zee M, Jia Y, Wang Y, et al. Alterations in Wnt/β-catenin and Pten signaling play distinct roles in endometrial cancer initiation and progression. J Pathol 2013; 230: 48-58.
15. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther 2012; 12: 51-62.
16. Wang Y, Hanifi-Moghaddam P, Hanekamp EE, et al. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 2009; 15: 5784-93.
17. Hou X, Tan Y, Li M, Dey SK, Das SK. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol 2004; 18: 3035-49. (Pubitemid 39577924)
18. Chen H, Wang Y, Xue F. Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway. Oncol Rep 2013; 29: 507-14.
19. Pijnenborg JM, Kisters N, van Engeland M, Dunselman GA, de Haan J, de Goeij AF, Groothuis PG. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2004; 14: 947-56. (Pubitemid 39238184)
20. Chen HJ, Hsu LS, Shia YT, Lin MW, Lin CM. The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Pharmacol 2012; 84: 1143-53.
21. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC. Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 1990; 265: 19704-11. (Pubitemid 120013919)
22. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41. (Pubitemid 27456390)
23. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE, Roberts JM. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 2003; 12: 381-92. (Pubitemid 37238925)
24. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005; 8: 25-33. (Pubitemid 40991812)
25. Héron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, Fernandez A, Lamb NJ. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 2006; 26: 8267-80.
26. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52. (Pubitemid 35175970)
27. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6. (Pubitemid 41780780)
28. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12. (Pubitemid 350145909)
29. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5. (Pubitemid 40813563)
30. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009; 27: e259.
31. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013; 62: 111-23.
32. Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X, Matias-Guiu X. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009; 62: 777-85.
33. Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22: 522-9.
34. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669-73. (Pubitemid 41713332)
35. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011; 71: 4061-7.
36. Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One 2012; 7: e41593.
37. Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, Yin L, Feng Y, Chen X. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci 2011; 102: 557-64.
38. McBride OW, Merry D, Givol D. The gene human p53 cellular tumor antigen is located on chromosome short arm (17p13). Proc Natl Acad Sci U S A 1986; 83: 130-4. (Pubitemid 16141627)
39. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31. (Pubitemid 27131374)
40. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13.
41. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutation and microsatellite instability differs in uterine endometrial and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814-24. (Pubitemid 30091101)
42. Ragni N, Ferrero S, Prefumo F, Muschiato B, Gorlero F, Gualco M, Fulcheri E. The association between p53expression stage and histopatological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2005; 123: 111-6. (Pubitemid 41563104)
43. Kohlberger P, Gitsch G, Loesch A, Tempfer C, Kaider A, Reinthaller A, Kainz C, Breitenecker G. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 1996; 62: 213-7. (Pubitemid 26274802)
44. Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, Bruchim I, Werner H. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor - directed targeted therapy. Eur J Cancer 2012; 48: 1570-80.
45. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS 3rd, James CD. CDK4 amplification is an alternative mechanism to p16 homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-7. (Pubitemid 24375209)
46. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56: 5475-83. (Pubitemid 27011383)
47. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRB. Cancer Res 1994; 54: 6078-82. (Pubitemid 24378633)
48. Tsuda H, Yamamoto K, Inoue T, Uchiyama I, Umesaki N. The role of p16-cyclinD/CDK-pRb pathway in the tumorogenesis of endometrial - type endometrial carcinoma. Br J Cancer 2000; 82: 675-82. (Pubitemid 30085207)
49. Netzer IM, Kerner H, Litwin L, Lowenstein L, Amit A. Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer 2011; 21: 1441-5.